{
    "abstract": "Background: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was \u226590% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies. Methods: Adults aged \u226550 (ZOE-50) and \u226570 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30 days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12 months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period. Results: Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race. Conclusions: No safety concerns arose, supporting the favorable benefit-risk profile of RZV.",
    "author_highlights": [
        {
            "endOffset": 27795,
            "sentence": "These data provide a comprehensive overview of the safety profile of RZV from two pivotal phase 3 studies.",
            "startOffset": 27689
        },
        {
            "endOffset": 27854,
            "sentence": "A favourable benefit-risk profile of RZV was demonstrated.",
            "startOffset": 27796
        },
        {
            "endOffset": 27942,
            "sentence": "This overview will help healthcare practitioners in making informed clinical decisions.",
            "startOffset": 27855
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Jeffrey I.",
                    "initial": "J.I.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1056/NEJMcp1302674",
            "firstpage": "255",
            "issn": "00284793",
            "lastpage": "263",
            "pmid": "23863052",
            "pub_year": 2013,
            "title": "Herpes Zoster",
            "volume": "369"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Berhanu G.",
                    "initial": "B.G.",
                    "last": "Gebremeskel"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1136/bmjopen-2014-004833",
            "issn": "20446055",
            "pmid": "24916088",
            "pub_year": 2014,
            "title": "Systematic review of incidence and complications of herpes zoster: Towards a global perspective",
            "volume": "4"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Barbara H.",
                    "initial": "B.H.",
                    "last": "Johnson"
                },
                {
                    "first": "Liisa",
                    "initial": "L.",
                    "last": "Palmer"
                },
                {
                    "first": "Justin",
                    "initial": "J.",
                    "last": "Gatwood"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Lenhart"
                },
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1186/s12879-015-1262-8",
            "issn": "14712334",
            "pmid": "26546419",
            "pub_year": 2015,
            "title": "Annual incidence rates of herpes zoster among an immunocompetent population in the United States",
            "volume": "15"
        },
        "b0020": {
            "authors": [
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "D\u00edez-Domingo"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Vanden Abeele"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Barba-Gomez"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Downey"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Ghesquiere"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gorfinkel"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Yeo"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1056/NEJMoa1603800",
            "firstpage": "1019",
            "issn": "00284793",
            "lastpage": "1032",
            "pmid": "27626517",
            "pub_year": 2016,
            "title": "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older",
            "volume": "375"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0030": null,
        "b0035": null,
        "b0040": {
            "authors": [
                {
                    "first": "Edward A.",
                    "initial": "E.A.",
                    "last": "Stadtmauer"
                },
                {
                    "first": "Keith M.",
                    "initial": "K.M.",
                    "last": "Sullivan"
                },
                {
                    "first": "Francisco M.",
                    "initial": "F.M.",
                    "last": "Marty"
                },
                {
                    "first": "Sanjeet S.",
                    "initial": "S.S.",
                    "last": "Dadwal"
                },
                {
                    "first": "Genovefa A.",
                    "initial": "G.A.",
                    "last": "Papanicolaou"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Shea"
                },
                {
                    "first": "Sherif B.",
                    "initial": "S.B.",
                    "last": "Mossad"
                },
                {
                    "first": "Charalambos",
                    "initial": "C.",
                    "last": "Andreadis"
                },
                {
                    "first": "Jo Anne H.",
                    "initial": "J.A.H.",
                    "last": "Young"
                },
                {
                    "first": "Francis K.",
                    "initial": "F.K.",
                    "last": "Buadi"
                },
                {
                    "first": "Mohamed El",
                    "initial": "M.E.",
                    "last": "Idrissi"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": "Elchonon M.",
                    "initial": "E.M.",
                    "last": "Berkowitz"
                }
            ],
            "doi": "10.1182/blood-2014-04-573048",
            "firstpage": "2921",
            "issn": "00064971",
            "lastpage": "2929",
            "pmid": "25237196",
            "pub_year": 2014,
            "title": "A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients",
            "volume": "124"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jos\u00e9 M.",
                    "initial": "J.M.",
                    "last": "Bayas"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Collins"
                },
                {
                    "first": "Maria Luisa Rodriguez",
                    "initial": "M.L.R.",
                    "last": "De La Pinta"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Johann F.",
                    "initial": "J.F.",
                    "last": "Mols"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1093/infdis/jit365",
            "firstpage": "1953",
            "issn": "00221899",
            "lastpage": "1961",
            "pmid": "23904292",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550 years of age",
            "volume": "208"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J. Anneke R.",
                    "initial": "J.A.R.",
                    "last": "Van den Hoek"
                },
                {
                    "first": "Jan H.",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Plassmann"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.019",
            "firstpage": "1745",
            "issn": "0264410X",
            "lastpage": "1753",
            "pmid": "24508036",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study",
            "volume": "32"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Ventzislav",
                    "initial": "V.",
                    "last": "Vassilev"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1093/infdis/jis497",
            "firstpage": "1280",
            "issn": "00221899",
            "lastpage": "1290",
            "pmid": "22872734",
            "pub_year": 2012,
            "title": "A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults",
            "volume": "206"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Martin J.",
                    "initial": "M.J.",
                    "last": "Prince"
                },
                {
                    "first": "Fan",
                    "initial": "F.",
                    "last": "Wu"
                },
                {
                    "first": "Yanfei",
                    "initial": "Y.",
                    "last": "Guo"
                },
                {
                    "first": "Luis M.",
                    "initial": "L.M.",
                    "last": "Gutierrez Robledo"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "O'Donnell"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Sullivan"
                },
                {
                    "first": "Salim",
                    "initial": "S.",
                    "last": "Yusuf"
                }
            ],
            "doi": "10.1016/S0140-6736(14)61347-7",
            "firstpage": "549",
            "issn": "01406736",
            "lastpage": "562",
            "pmid": "25468153",
            "pub_year": 2015,
            "title": "The burden of disease in older people and implications for health policy and practice",
            "volume": "385"
        },
        "b0065": {
            "authors": [
                {
                    "first": "A\u00efda",
                    "initial": "A.",
                    "last": "Sol\u00e9-Aur\u00f3"
                },
                {
                    "first": "Pierre Carl",
                    "initial": "P.C.",
                    "last": "Michaud"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Hurd"
                },
                {
                    "first": "Eileen",
                    "initial": "E.",
                    "last": "Crimmins"
                }
            ],
            "doi": "10.1007/s13524-015-0372-7",
            "firstpage": "593",
            "issn": "00703370",
            "lastpage": "611",
            "pmid": "25715676",
            "pub_year": 2015,
            "title": "Disease Incidence and Mortality Among Older Americans and Europeans",
            "volume": "52"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Sasmita",
                    "initial": "S.",
                    "last": "Biswal"
                },
                {
                    "first": "Chaitali",
                    "initial": "C.",
                    "last": "Godnaik"
                }
            ],
            "doi": "10.3332/ecancer.2013.310",
            "issn": "17546605",
            "pub_year": 2013,
            "title": "Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards",
            "volume": "7"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Serap",
                    "initial": "S.",
                    "last": "Gen\u00e7er"
                },
                {
                    "first": "Taflan",
                    "initial": "T.",
                    "last": "Salep\u00e7i"
                },
                {
                    "first": "Serdar",
                    "initial": "S.",
                    "last": "\u00d6zer"
                }
            ],
            "doi": "10.1016/S0163-4453(03)00044-6",
            "firstpage": "65",
            "issn": "01634453",
            "lastpage": "72",
            "pmid": "12850165",
            "pub_year": 2003,
            "title": "Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients",
            "volume": "47"
        },
        "b0085": {
            "authors": [
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Perola"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Nousiainen"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Pentik\u00e4inen"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Laatikainen"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Katila"
                }
            ],
            "doi": "10.1007/s10096-005-0045-3",
            "firstpage": "766",
            "issn": "09349723",
            "lastpage": "768",
            "pmid": "16328561",
            "pub_year": 2005,
            "title": "Infections and bacterial colonization during cytotoxic therapy in patients with acute leukemia",
            "volume": "24"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Agmon-Levin"
                },
                {
                    "first": "Shaye",
                    "initial": "S.",
                    "last": "Kivity"
                },
                {
                    "first": "Yehuda",
                    "initial": "Y.",
                    "last": "Shoenfeld"
                }
            ],
            "firstpage": "183",
            "issn": "15651088",
            "lastpage": "185",
            "pmid": "19544711",
            "pub_year": 2009,
            "title": "Influenza vaccine and autoimmunity",
            "volume": "11"
        },
        "b0095": {
            "authors": [
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Israeli"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Agmon-Levin"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Blank"
                },
                {
                    "first": "Yehuda",
                    "initial": "Y.",
                    "last": "Shoenfeld"
                }
            ],
            "doi": "10.1177/0961203309345724",
            "firstpage": "1217",
            "issn": "09612033",
            "lastpage": "1225",
            "pmid": "19880572",
            "pub_year": 2009,
            "title": "Adjuvants and autoimmunity",
            "volume": "18"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Yehuda",
                    "initial": "Y.",
                    "last": "Shoenfeld"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Agmon-Levin"
                }
            ],
            "doi": "10.1016/j.jaut.2010.07.003",
            "firstpage": "4",
            "issn": "08968411",
            "lastpage": "8",
            "pmid": "20708902",
            "pub_year": 2011,
            "title": "'ASIA' - Autoimmune/inflammatory syndrome induced by adjuvants",
            "volume": "36"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Simonetta",
                    "initial": "S.",
                    "last": "Salemi"
                },
                {
                    "first": "Raffaele",
                    "initial": "R.",
                    "last": "D'Amelio"
                }
            ],
            "doi": "10.3109/08830181003746304",
            "firstpage": "247",
            "issn": "08830185",
            "lastpage": "269",
            "pmid": "20521925",
            "pub_year": 2010,
            "title": "Could autoimmunity be induced by vaccination",
            "volume": "29"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Maria Genalin",
                    "initial": "M.G.",
                    "last": "Angelo"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "David"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Zima"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Baril"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Dubin"
                },
                {
                    "first": "Felix",
                    "initial": "F.",
                    "last": "Arellano"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Struyf"
                }
            ],
            "doi": "10.1002/pds.3554",
            "firstpage": "466",
            "issn": "10538569",
            "lastpage": "479",
            "pmid": "24644063",
            "pub_year": 2014,
            "title": "Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme",
            "volume": "23"
        },
        "b0115": {
            "authors": [
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Wraith"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Goldman"
                },
                {
                    "first": "Paul Henri",
                    "initial": "P.H.",
                    "last": "Lambert"
                }
            ],
            "doi": "10.1016/S0140-6736(03)14802-7",
            "firstpage": "1659",
            "issn": "01406736",
            "lastpage": "1666",
            "pmid": "14630450",
            "pub_year": 2003,
            "title": "Vaccination and autoimmune disease: What is the evidence?",
            "volume": "362"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Arnaud M.",
                    "initial": "A.M.",
                    "last": "Didierlaurent"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Collignon"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Sandrine",
                    "initial": "S.",
                    "last": "Wouters"
                },
                {
                    "first": "Kaat",
                    "initial": "K.",
                    "last": "Fierens"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Fochesato"
                },
                {
                    "first": "Najoua",
                    "initial": "N.",
                    "last": "Dendouga"
                },
                {
                    "first": "Christelle",
                    "initial": "C.",
                    "last": "Langlet"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Malissen"
                },
                {
                    "first": "Bart N.",
                    "initial": "B.N.",
                    "last": "Lambrecht"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Morel"
                }
            ],
            "doi": "10.4049/jimmunol.1400948",
            "firstpage": "1920",
            "issn": "00221767",
            "lastpage": "1930",
            "pmid": "25024381",
            "pub_year": 2014,
            "title": "Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells",
            "volume": "193"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Fernanda",
                    "initial": "F.",
                    "last": "Tavares Da Silva"
                },
                {
                    "first": "Filip",
                    "initial": "F.",
                    "last": "De Keyser"
                },
                {
                    "first": "Paul Henri",
                    "initial": "P.H.",
                    "last": "Lambert"
                },
                {
                    "first": "William H.",
                    "initial": "W.H.",
                    "last": "Robinson"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Westhovens"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Sindic"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.01.042",
            "firstpage": "1870",
            "issn": "0264410X",
            "lastpage": "1876",
            "pmid": "23391600",
            "pub_year": 2013,
            "title": "Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines",
            "volume": "31"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Cynthia S.",
                    "initial": "C.S.",
                    "last": "Crowson"
                },
                {
                    "first": "Eric L.",
                    "initial": "E.L.",
                    "last": "Matteson"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Myasoedova"
                },
                {
                    "first": "Clement J.",
                    "initial": "C.J.",
                    "last": "Michet"
                },
                {
                    "first": "Floranne C.",
                    "initial": "F.C.",
                    "last": "Ernste"
                },
                {
                    "first": "Kenneth J.",
                    "initial": "K.J.",
                    "last": "Warrington"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Davis"
                },
                {
                    "first": "Gene G.",
                    "initial": "G.G.",
                    "last": "Hunder"
                },
                {
                    "first": "Terry M.",
                    "initial": "T.M.",
                    "last": "Therneau"
                },
                {
                    "first": "Sherine E.",
                    "initial": "S.E.",
                    "last": "Gabriel"
                }
            ],
            "doi": "10.1002/art.30155",
            "firstpage": "633",
            "issn": "00043591",
            "lastpage": "639",
            "pmid": "21360492",
            "pub_year": 2011,
            "title": "The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases",
            "volume": "63"
        },
        "b0135": null,
        "b0140": {
            "authors": [
                {
                    "first": "Mark P.J.",
                    "initial": "M.P.J.",
                    "last": "Vanderpump"
                }
            ],
            "doi": "10.1093/bmb/ldr030",
            "firstpage": "39",
            "issn": "00071420",
            "lastpage": "51",
            "pmid": "21893493",
            "pub_year": 2011,
            "title": "The epidemiology of thyroid disease",
            "volume": "99"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Elizabeth K.",
                    "initial": "E.K.",
                    "last": "Rasch"
                },
                {
                    "first": "Rosemarie",
                    "initial": "R.",
                    "last": "Hirsch"
                },
                {
                    "first": "Ryne",
                    "initial": "R.",
                    "last": "Paulose-Ram"
                },
                {
                    "first": "Marc C.",
                    "initial": "M.C.",
                    "last": "Hochberg"
                }
            ],
            "doi": "10.1002/art.10897",
            "firstpage": "917",
            "issn": "00043591",
            "lastpage": "926",
            "pmid": "12687533",
            "pub_year": 2003,
            "title": "Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: Effect of different methods of case classification",
            "volume": "48"
        }
    },
    "body_text": [
        {
            "endOffset": 34839,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "pIMDs were defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest that may or may not have an autoimmune etiology.",
            "startOffset": 34657,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 44535,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "pIMDs were reported by 90 (0.6%) RZV and 105 (0.7%) placebo recipients up to 1Y post-last dose, and by 179 (1.2%) RZV and 202 (1.4%) placebo recipients during the entire study period.",
            "startOffset": 44352,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 37147,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "In the RZV group, the most frequently reported solicited general symptoms were myalgia and fatigue, reported after 32.9% (95% CI: 31.9\u201333.8) and 32.2% (95% CI: 31.3\u201333.2) of doses, respectively.",
            "startOffset": 36953,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 38615,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Unsolicited AEs were balanced between groups during the subsequent 23D (D7-D29) post-vaccination period (3,076 [21.0%] versus 3,280 [22.4%]) (Fig. 1).",
            "startOffset": 38465,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 45936,
            "parents": [],
            "secId": "s0070",
            "sentence": "Overall, the pooled safety data from ZOE-50/70 studies did not reveal any safety concerns.",
            "startOffset": 45846,
            "title": "Discussion"
        },
        {
            "endOffset": 50324,
            "parents": [],
            "secId": "s0070",
            "sentence": "The results of these pooled analyses need to be considered in the context of study strengths and weaknesses.",
            "startOffset": 50216,
            "title": "Discussion"
        },
        {
            "endOffset": 48241,
            "parents": [],
            "secId": "s0070",
            "sentence": "The neutropenia and neutropenic sepsis in this participant were likely the result of the induction chemotherapy for the treatment of AML.",
            "startOffset": 48104,
            "title": "Discussion"
        },
        {
            "endOffset": 32713,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.",
            "startOffset": 32578,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36076,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Additional details are presented in the Supplementary Material.",
            "startOffset": 36013,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34656,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Relatedness of other AEs was determined based on study investigators clinical judgment, in a blinded manner.",
            "startOffset": 34548,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 51569,
            "parents": [],
            "secId": "s0075",
            "sentence": "LO is an employee of CureVac AG.",
            "startOffset": 51537,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 34096,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "SAEs were collected from the first vaccine dose up to 1 year (Y) post-last vaccination.",
            "startOffset": 34009,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 35585,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Analyses of SAEs, fatal AEs, and pIMDs were performed up to 30D and 1Y post-last dose.",
            "startOffset": 35499,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35923,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Exploratory analyses of unsolicited AEs reported within the 30D post-vaccination period, SAEs and pIMDs reported within 1Y post-last dose assessed the relative risks (RRs) and frequencies of selected events of interest using MedDRA queries.",
            "startOffset": 35683,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 47084,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 46929,
                    "startOffset": 46922
                },
                "b0065": {
                    "endOffset": 46929,
                    "startOffset": 46922
                }
            },
            "secId": "s0070",
            "sentence": "The nature of the SAEs reported in the pooled ZOE-50/70 studies reflects those observed in the general older adult population [12,13], and overall, no apparent differences were observed between the two groups during any of the time intervals assessed, irrespective of age, gender or race.",
            "startOffset": 46796,
            "title": "Discussion"
        },
        {
            "endOffset": 32236,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 32183,
                    "startOffset": 32178
                },
                "b0025": {
                    "endOffset": 32183,
                    "startOffset": 32178
                }
            },
            "secId": "s0015",
            "sentence": "A full list of eligibility criteria was previously presented [4,5], and is provided here in the Supplementary Material.",
            "startOffset": 32117,
            "title": "Study design and participants"
        },
        {
            "endOffset": 49524,
            "parents": [],
            "secId": "s0070",
            "sentence": "In eligible participants with pre-existing pIMDs at study entry, exacerbations as well as new onset of other pIMDs were recorded during the entire study period.",
            "startOffset": 49364,
            "title": "Discussion"
        },
        {
            "endOffset": 48819,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 48546,
                    "startOffset": 48539
                },
                "b0095": {
                    "endOffset": 48546,
                    "startOffset": 48539
                },
                "b0100": {
                    "endOffset": 48546,
                    "startOffset": 48539
                },
                "b0105": {
                    "endOffset": 48818,
                    "startOffset": 48811
                },
                "b0110": {
                    "endOffset": 48818,
                    "startOffset": 48811
                }
            },
            "secId": "s0070",
            "sentence": "Although concerns have been raised regarding potential associations between vaccine adjuvants and the occurrence of pIMDs [18\u201320], the association between vaccination and pIMDs has largely been extrapolated from isolated case reports, and large epidemiological studies and pooled analyses only showed such an association for a very limited number of vaccine and autoimmune disease combinations [21,22].",
            "startOffset": 48417,
            "title": "Discussion"
        },
        {
            "endOffset": 35109,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 35108,
                    "startOffset": 35105
                }
            },
            "secId": "s0025",
            "sentence": "AEs to be recorded as pIMDs were pre-defined in the study protocol (Supplementary Table 1) and, in addition, study investigators were instructed to use their medical judgment to determine whether other events could fall in this category and to record them as pIMDs [8].",
            "startOffset": 34840,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 49363,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 49362,
                    "startOffset": 49358
                }
            },
            "secId": "s0070",
            "sentence": "Nonetheless, in the ZOE-50/70 studies, pIMDs were monitored through standard data collection methods and disease-specific standard questionnaires for the collection of the pIMD safety data [25].",
            "startOffset": 49169,
            "title": "Discussion"
        },
        {
            "endOffset": 36352,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Most (73.7%) participants were white/Caucasian.",
            "startOffset": 36305,
            "title": "Study population"
        },
        {
            "endOffset": 37692,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Overall, there were no differences in the proportions of RZV recipients reporting any grade or grade 3 solicited local events between dose 1 and dose 2.",
            "startOffset": 37540,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 43406,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The most frequently reported fatal AEs by SOC in each study group were neoplasms benign, malignant and unspecified (RZV: 182 [1.2%], Placebo: 177 [1.2%]), followed by cardiac disorders (RZV: 174 [1.2%], Placebo: 193 [1.3%]), and infections and infestations (RZV: 103 [0.7%], Placebo: 107 [0.7%]).",
            "startOffset": 43110,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 44075,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The study participant died 97D post-dose 1 due to neutropenic sepsis.",
            "startOffset": 44006,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 47509,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, given the high number of comparisons, the probability of obtaining a false significant increase in the incidence of a particular event is inflated.",
            "startOffset": 47353,
            "title": "Discussion"
        },
        {
            "endOffset": 30790,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 30789,
                    "startOffset": 30784
                },
                "b0015": {
                    "endOffset": 30789,
                    "startOffset": 30784
                }
            },
            "secId": "s0005",
            "sentence": "HZ incidence increases substantially with age, from 3 to 5 cases per 1000 person-years in the general population of all ages [2], to 4\u20138 cases per 1000 person-years in adults \u226550 years of age (YOA) and 8\u201312 cases per 1000 person-years for those \u226580 YOA [2,3].",
            "startOffset": 30531,
            "title": "Introduction"
        },
        {
            "endOffset": 50459,
            "parents": [],
            "secId": "s0070",
            "sentence": "The ZOE-50/70 clinical trials included a large and global population of relevant age, predominantly of Caucasian and Asian ancestries.",
            "startOffset": 50325,
            "title": "Discussion"
        },
        {
            "endOffset": 43570,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The most frequently reported fatal AEs by PT were cardiac failure, pneumonia, myocardial infarction, death (with no specified cause), and cardiac arrest (Table 3).",
            "startOffset": 43407,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 31990,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) were phase 3, randomized, placebo-controlled, observer-blinded clinical trials conducted concurrently at the same sites in 18 countries in Europe, North and South America, Asia and Australia.",
            "startOffset": 31753,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46321,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 46320,
                    "startOffset": 46315
                },
                "b0025": {
                    "endOffset": 46320,
                    "startOffset": 46315
                }
            },
            "secId": "s0070",
            "sentence": "Unsolicited symptoms were more frequent in RZV recipients, driven by local and systemic reactions reported during D0-D6 post-vaccination by participants who were not part of the reactogenicity sub-cohort [4,5].",
            "startOffset": 46111,
            "title": "Discussion"
        },
        {
            "endOffset": 52060,
            "parents": [],
            "secId": "s0075",
            "sentence": "LO, TCH, HL and FTdS hold shares or stock options from GSK as part of their current or former employee remuneration.",
            "startOffset": 51944,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 51305,
            "parents": [],
            "secId": "s0070",
            "sentence": "The pooled analyses of the phase 3 ZOE-50/70 clinical trials did not identify any safety concerns, and, along with the high vaccine efficacy demonstrated in these trials, these results support the favorable benefit-risk profile of RZV in all age-groups studied.",
            "startOffset": 51044,
            "title": "Discussion"
        },
        {
            "endOffset": 40816,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Within 1Y post-last dose, SAE incidence was similar between the RZV and Placebo groups in both age cohorts, in both males and females, and in participants of any race (Table 2).",
            "startOffset": 40639,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 40639,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "During the entire study period, SAEs considered causally related to vaccination by investigators were reported by 15 (0.1%) participants in each group (Table 2, Supplementary Table 4).",
            "startOffset": 40455,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 44351,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Up to 30D post-last dose, pIMDs were reported by 30 (0.2%) participants in each group.",
            "startOffset": 44265,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 42566,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, the percentage of participants reporting fatal AEs was similar between RZV and placebo recipients during all time periods analyzed.",
            "startOffset": 42426,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 45606,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Over 95% of participants with a pre-existing pIMD did not experience a possible exacerbation of a pre-existing pIMD nor an onset of a new pIMD during the study.",
            "startOffset": 45446,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 31713,
            "parents": [],
            "secId": "s0005",
            "sentence": "We present here a comprehensive analysis of the safety data from pooled ZOE 50/70 studies.",
            "startOffset": 31623,
            "title": "Introduction"
        },
        {
            "endOffset": 36192,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "A total of 14,645 RZV and 14,660 placebo recipients were included in the pooled analysis.",
            "startOffset": 36103,
            "title": "Study population"
        },
        {
            "endOffset": 46721,
            "parents": [],
            "secId": "s0070",
            "sentence": "In line with these findings, the pooled analysis presented here shows a similar profile of transient local and systemic reactions to the vaccine (including those of grade 3 intensity) occurring during D0-D6 post-vaccination.",
            "startOffset": 46497,
            "title": "Discussion"
        },
        {
            "endOffset": 32386,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The two studies were conducted in an identical manner, and adults \u226570 YOA were randomly enrolled to participate in either the ZOE-50 or ZOE-70 study.",
            "startOffset": 32237,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37539,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Local and general symptoms in the RZV group were mostly mild to moderate in intensity and transient (median duration was of 3 days or less for local and 2 days or less for general symptoms, including grade 3 symptoms).",
            "startOffset": 37321,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 44688,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Up to 1Y post-last dose, pIMDs considered related to vaccination by study investigators were reported by 15 (0.1%) participants in each group (Table 4).",
            "startOffset": 44536,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 47352,
            "parents": [],
            "secId": "s0070",
            "sentence": "A descriptive analysis revealed that supraventricular tachycardia was the only SAE by PT with an increased risk in RZV recipients up to 1Y post-last vaccination.",
            "startOffset": 47191,
            "title": "Discussion"
        },
        {
            "endOffset": 44851,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Overall, occurrences of pIMDs during the entire study period were similar between RZV and placebo recipients irrespective of age cohort, gender, or race (Table 4).",
            "startOffset": 44688,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 31622,
            "parents": [],
            "secId": "s0005",
            "sentence": "The similar enrollment criteria, study procedures, and safety follow-up period for the ZOE-50/70 trials allowed us to pool study data.",
            "startOffset": 31488,
            "title": "Introduction"
        },
        {
            "endOffset": 51536,
            "parents": [],
            "secId": "s0075",
            "sentence": "FJDL reports receiving grant support from GSK and Novartis outside the submitted work.",
            "startOffset": 51450,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 33571,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Unsolicited AEs were collected for 30D after each vaccination and graded on a scale from 1 (mild: not interfering with everyday activities) to 3 (severe: significant at rest and preventing normal everyday activities).",
            "startOffset": 33354,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 38983,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Unsolicited AEs not categorized as solicited AEs in the reactogenicity sub-cohort, those occurring in >1% of RZV recipients and more frequently than in placebo recipients were, by PT: injection site pruritus, pain, injection site warmth, pain in extremity, malaise, arthralgia, back pain, dizziness, upper respiratory tract infection, and oropharyngeal pain (Table 1).",
            "startOffset": 38615,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 48417,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 48416,
                    "startOffset": 48409
                },
                "b0080": {
                    "endOffset": 48416,
                    "startOffset": 48409
                },
                "b0085": {
                    "endOffset": 48416,
                    "startOffset": 48409
                }
            },
            "secId": "s0070",
            "sentence": "Neutropenic fever and sepsis are common AEs for therapeutic treatment [15\u201317].",
            "startOffset": 48339,
            "title": "Discussion"
        },
        {
            "endOffset": 32467,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 32466,
                    "startOffset": 32461
                },
                "b0025": {
                    "endOffset": 32466,
                    "startOffset": 32461
                }
            },
            "secId": "s0015",
            "sentence": "Additional study design details are presented in the primary publications [4,5].",
            "startOffset": 32387,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46796,
            "parents": [],
            "secId": "s0070",
            "sentence": "No clinically significant imbalance in other unsolicited AEs was observed.",
            "startOffset": 46722,
            "title": "Discussion"
        },
        {
            "endOffset": 52694,
            "parents": [],
            "secId": "s0075",
            "sentence": "SAM reports research grant from Pfizer, personal fees for continuing professional development talks on adult immunization from Pfizer and Merck, and consulting fees from Pfizer and Merck outside the submitted work, as well as grant from GSK outside the submitted work.",
            "startOffset": 52426,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 34008,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Unsolicited AEs with medically attended visits (defined as hospitalizations, emergency room visits, or visits to or from medical personnel), other than routine health care visits, were recorded from first vaccine dose up to 6 months (M) post-last vaccination.",
            "startOffset": 33749,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 37320,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Grade 3 fatigue was reported after 3.0% (95% CI: 2.6\u20133.3) of documented doses in the RZV group and after 0.5% (95% CI: 0.4\u20130.7) in the placebo group (Supplementary Fig. 2).",
            "startOffset": 37148,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 41471,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Statistically significant imbalances based on the nominal unadjusted p-value (p < 0.05) between RZV and placebo recipients were found for four individual SAEs by PT (Table 2).",
            "startOffset": 41296,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 50216,
            "parents": [],
            "secId": "s0070",
            "sentence": "Overall, these data do not show an increased risk of developing a new pIMD or exacerbating an underlying pIMD in RZV recipients \u226550 YOA.",
            "startOffset": 50080,
            "title": "Discussion"
        },
        {
            "endOffset": 52219,
            "parents": [],
            "secId": "s0075",
            "sentence": "HL is a current employee of Pfizer and receives stock as part of his employee remuneration.",
            "startOffset": 52128,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 47190,
            "parents": [],
            "secId": "s0070",
            "sentence": "Similarly, SAEs considered related to study vaccination by the investigator were balanced between groups.",
            "startOffset": 47085,
            "title": "Discussion"
        },
        {
            "endOffset": 36621,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 36541,
                    "startOffset": 36536
                },
                "b0025": {
                    "endOffset": 36541,
                    "startOffset": 36536
                }
            },
            "secId": "s0045",
            "sentence": "In line with previously reported reactogenicity results from the ZOE-50/70 studies [4,5], RZV was more reactogenic than placebo in the pooled reactogenicity sub-cohort.",
            "startOffset": 36453,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 43644,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One fatal AE was assessed as possibly vaccine-related by the investigator.",
            "startOffset": 43570,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 41113,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In both study groups, the most frequently reported SAEs by SOC were: infections and infestations (RZV: 299 [2.04%], Placebo: 302 [2.06%]), cardiac disorders (RZV: 290 [1.98%], Placebo: 318 [2.17%]), and neoplasms benign, malignant and unspecified (RZV: 226 [1.54%], Placebo: 225 [1.53%], Fig. 2).",
            "startOffset": 40817,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 46111,
            "parents": [],
            "secId": "s0070",
            "sentence": "A plain language summary contextualizing the results and potential clinical research relevance and impact is displayed in the Focus on Patient Section (Supplementary Fig. 4).",
            "startOffset": 45937,
            "title": "Discussion"
        },
        {
            "endOffset": 32577,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The clinical study reports are available at http://www.gsk-clinicalstudyregister.com (IDs 110390 and 113077).",
            "startOffset": 32468,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32116,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Adults aged \u2265 50 YOA (ZOE-50) or \u2265 70 YOA (ZOE-70) were randomized and vaccinated with RZV or placebo (Supplementary Fig. 1).",
            "startOffset": 31991,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43109,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The occurrence of fatal AEs was similar between groups in both age cohorts, but higher in participants \u226570 YOA compared to those 50\u201369 YOA (Table 3).",
            "startOffset": 42960,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 35682,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In addition, analyses of fatal AEs and pIMDs were also performed during the entire study period.",
            "startOffset": 35586,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 52754,
            "parents": [],
            "secId": "s0075",
            "sentence": "WY reports financial support from GSK to perform the study.",
            "startOffset": 52695,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 45015,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The most frequently reported pIMDs by PT were polymyalgia rheumatica, rheumatoid arthritis, psoriasis, and autoimmune thyroiditis (Table 4, Supplementary Table 5).",
            "startOffset": 44852,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 36805,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Pain was the most frequent solicited local symptom reported after 68.1% (95% CI: 67.1\u201369.0) of documented doses in the RZV group and after 6.9% (95% CI: 6.4\u20137.4) in the Placebo group.",
            "startOffset": 36622,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 30530,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 30529,
                    "startOffset": 30526
                }
            },
            "secId": "s0005",
            "sentence": "Its most common complication is postherpetic neuralgia, a chronic pain that can persist for months or years after the rash has resolved [1].",
            "startOffset": 30390,
            "title": "Introduction"
        },
        {
            "endOffset": 33353,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Solicited adverse events (AEs) were collected for 7 days (D) after each vaccination (D0-D6) in the reactogenicity sub-cohort, consisting of participants who completed diary cards; severe AEs are described in the Supplementary Material.",
            "startOffset": 33118,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 42403,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "PTs under which SAEs were reported more frequently in placebo than in RZV recipients, were aortic stenosis (0 [0.00%] versus 10 [0.07%]; RR = 0.00 [95%CI:0.00\u20130.35]; p = 0.0020), cardio-respiratory arrest (0 [0.00%] versus 6 [0.04%]; RR = 0.00 [95%CI:0.00\u20130.65]; p = 0.0313), and retinal detachment (1 [0.01%] versus 8 [0.05%]; RR = 0.13 [95%CI:0.00\u20130.93]; p = 0.0392).",
            "startOffset": 42034,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 49911,
            "parents": [],
            "secId": "s0070",
            "sentence": "The occurrence of new onset pIMDs was similar between groups, irrespective of time interval assessed, participant age, gender, or race.",
            "startOffset": 49776,
            "title": "Discussion"
        },
        {
            "endOffset": 39530,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Injection site pain was the only PT under which grade 3 unsolicited AEs were reported by >1% of RZV recipients and had a higher frequency as compared to the Placebo group (Table 1).",
            "startOffset": 39349,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 39348,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The most frequent grade 3 unsolicited AEs in the RZV group were injection site pain, pyrexia, and headache.",
            "startOffset": 39241,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 36436,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Demographic characteristics were comparable between groups (Supplementary Table 2).",
            "startOffset": 36353,
            "title": "Study population"
        },
        {
            "endOffset": 44005,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "He was hospitalized and withdrawn from study treatment.",
            "startOffset": 43950,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 52425,
            "parents": [],
            "secId": "s0075",
            "sentence": "JEM reports receiving honoraria and fees paid to her institution from GSK, Sanofi Pasteur, Merck and Pfizer, as well as travel support from GSK, Sanofi Pasteur, Merck and Pfizer outside the submitted work.",
            "startOffset": 52220,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 51943,
            "parents": [],
            "secId": "s0075",
            "sentence": "JDD reports receiving personal fees from GSK for an advisory board on a pharmacoeconomic study with Synflorix in Spain, as well as grants and personal fees from Sanofi Pasteur MSD for an epidemiological study on herpes zoster and an advisory board on Zostavax, respectively, outside the submitted work.",
            "startOffset": 51641,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 42959,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "During the entire study period, fatal AEs were reported by 634 (4.3%) participants in the RZV group and by 680 (4.6%) participants in the Placebo group.",
            "startOffset": 42807,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 43949,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "A 90-year-old male study participant with a past medical history of stable immune-mediated thrombocytopenia for approximately 10Y prior to vaccination developed pancytopenia and was diagnosed, on the basis of a bone marrow biopsy, with acute myeloid leukemia (AML) 75D after receiving the first RZV dose.",
            "startOffset": 43645,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 40454,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Within 1Y post-last dose, SAEs were reported by 1482 (10.1%) and 1525 (10.4%) participants in the RZV and Placebo groups, respectively (RR = 0.97 [95%CI:0.91\u20131.05]; p = 0.46).",
            "startOffset": 40279,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 42807,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within 1Y post-last dose, fatal AEs were reported by 153 (1.1%) and 168 (1.1%) participants in the RZV and Placebo groups, respectively (Table 3).",
            "startOffset": 42661,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 51449,
            "parents": [],
            "secId": "s0075",
            "sentence": "MLF, LC, FD, MEI and FTdS are employees, and LO, TCH and HL are former employees, of the GSK group of companies.",
            "startOffset": 51337,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 45835,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Among participants with pre-existing pIMDs, onset of new pIMDs were reported by 16 (1.6%) RZV and 23 (2.4%) placebo recipients, and possible exacerbation of pre-existing pIMD by 27 (2.8%) of participants in each group (Table 5).",
            "startOffset": 45607,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 42033,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "By grouping supraventricular tachycardia with other PTs that are pathophysiologically similar to or synonymous with supraventricular tachycardia (i.e. arrhythmia supraventricular, atrial fibrillation, atrial flutter, atrial tachycardia, cardiac flutter, tachyarrhythmia, and tachycardia paroxysmal), the data showed no imbalance between RZV and placebo recipients (69 [0.47%] versus 66 [0.45%]; RR = 1.05 [95%CI:0.74\u20131.49]; p = 0.86).",
            "startOffset": 41599,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 48103,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 48102,
                    "startOffset": 48099
                }
            },
            "secId": "s0070",
            "sentence": "One fatal AE (neutropenic sepsis) that occurred more than 3M post-vaccination, was considered related to vaccination by the study investigator [4].",
            "startOffset": 47956,
            "title": "Discussion"
        },
        {
            "endOffset": 40175,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Overall, the occurrence of SAEs was similar in both groups for all time periods analyzed.",
            "startOffset": 40086,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 36952,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Grade 3 pain was reported after 3.8% (95% CI: 3.5\u20134.3) of documented doses in the RZV group and after 0.2% (95% CI: 0.1\u20130.3) in the Placebo group.",
            "startOffset": 36806,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 30389,
            "parents": [],
            "secId": "s0005",
            "sentence": "HZ is typically characterized by a unilateral dermatomal vesicular rash, generally accompanied by pain.",
            "startOffset": 30286,
            "title": "Introduction"
        },
        {
            "endOffset": 41598,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Six (<0.05%) RZV recipients reported SAEs under the supraventricular tachycardia PT versus no participants in the Placebo arm.",
            "startOffset": 41472,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 33040,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "RZV contains 50 \u03bcg of gE antigen and the GSK proprietary AS01B Adjuvant System (containing 50 \u03bcg of 3-O-desacyl-4\u2032-monophosphoryl lipid A, 50 \u03bcg of Quillaja saponaria Molina, fraction 21 [licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation] and liposome).",
            "startOffset": 32730,
            "title": "Study vaccines"
        },
        {
            "endOffset": 31038,
            "parents": [],
            "secId": "s0005",
            "sentence": "An adjuvanted recombinant zoster vaccine, RZV (Shingrix, GSK), consisting of a truncated form of VZV glycoprotein E (gE) and the AS01B adjuvant system, is currently licensed in different regions worldwide for the prevention of HZ in adults \u226550 YOA.",
            "startOffset": 30790,
            "title": "Introduction"
        },
        {
            "endOffset": 49168,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 49167,
                    "startOffset": 49163
                }
            },
            "secId": "s0070",
            "sentence": "However, pre-clinical evidence suggests that RZV is unlikely to cause long-term inflammation, as the innate immune response and activity of pro-inflammatory cytokines are transient [24].",
            "startOffset": 48982,
            "title": "Discussion"
        },
        {
            "endOffset": 44264,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Overall, the occurrence of pIMDs (new onset and possible exacerbations) was similar between RZV and placebo recipients during all time periods analyzed.",
            "startOffset": 44112,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 49775,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 49774,
                    "startOffset": 49767
                },
                "b0135": {
                    "endOffset": 49774,
                    "startOffset": 49767
                },
                "b0140": {
                    "endOffset": 49774,
                    "startOffset": 49767
                },
                "b0145": {
                    "endOffset": 49774,
                    "startOffset": 49767
                }
            },
            "secId": "s0070",
            "sentence": "Overall, the most frequently reported pIMDs were those with the greatest prevalence in this age group [26\u201329].",
            "startOffset": 49665,
            "title": "Discussion"
        },
        {
            "endOffset": 38026,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The percentage of participants reporting unsolicited AEs during 30D post-vaccination was greater for RZV than for placebo recipients (7393 [50.5%] versus 4689 [32.0%]; RR: 1.58 [95%CI:1.52\u20131.64]; p < 0.0001).",
            "startOffset": 37818,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 34491,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 34490,
                    "startOffset": 34487
                }
            },
            "secId": "s0025",
            "sentence": "AEs were coded by Medical Dictionary for Regulatory Activities (MedDRA) dictionary both per System Organ Class (SOC) and Preferred Term (PT) [7].",
            "startOffset": 34346,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 36232,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The median follow-up duration was 4.4Y.",
            "startOffset": 36193,
            "title": "Study population"
        },
        {
            "endOffset": 42660,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within 30D post-last dose, 17 (0.1%) RZV and 21 (0.1%) placebo recipients reported fatal AEs.",
            "startOffset": 42567,
            "title": "Fatal adverse events"
        },
        {
            "endOffset": 33748,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Unsolicited AEs comprised both SAEs and non-serious AEs, including all local and systemic reactions reported by participants who were not part of the reactogenicity sub-cohort.",
            "startOffset": 33572,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 38137,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "RZV recipients reported unsolicited AEs more frequently, irrespective of age group, gender, or race (Table 1).",
            "startOffset": 38027,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 50079,
            "parents": [],
            "secId": "s0070",
            "sentence": "Additionally, in participants with pre-existing pIMDs, the occurrences of a possible exacerbation or a new onset of a different pIMD were also balanced between groups.",
            "startOffset": 49912,
            "title": "Discussion"
        },
        {
            "endOffset": 31488,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 31487,
                    "startOffset": 31482
                },
                "b0025": {
                    "endOffset": 31487,
                    "startOffset": 31482
                }
            },
            "secId": "s0005",
            "sentence": "In both studies, serious adverse events (SAEs) and potential immune-mediated diseases (pIMDs) were balanced between participants in the RZV and Placebo groups [4,5].",
            "startOffset": 31323,
            "title": "Introduction"
        },
        {
            "endOffset": 38323,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Unsolicited AEs more frequently reported by RZV recipients were injection site and general symptoms that were reported as solicited reactions in the reactogenicity sub-cohort (Table 1).",
            "startOffset": 38138,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 45445,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The most common pre-existing pIMDs at baseline by PT were psoriasis (RZV: 215 [21.9%], Placebo: 239 [24.9%]), spondyloarthropathy (RZV: 109 [11.1%], Placebo: 89 [9.3%]), and rheumatoid arthritis (RZV: 96 [9.8%], Placebo: 94 [9.8%]).",
            "startOffset": 45213,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 38464,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "More RZV than placebo recipients reported unsolicited AEs during the first week (D0-D6) post-vaccination (5861 [40.0%] versus 2230 [15.2%]).",
            "startOffset": 38324,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 50859,
            "parents": [],
            "secId": "s0070",
            "sentence": "Since incidence rates of some medical conditions, such as certain pIMDs and allergic reactions vary roughly from 1 to 20 per 100,000 person-years in the general population, these AEs will require post-licensure safety monitoring, during which a larger population will be vaccinated.",
            "startOffset": 50577,
            "title": "Discussion"
        },
        {
            "endOffset": 47955,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 47901,
                    "startOffset": 47894
                },
                "b0070": {
                    "endOffset": 47901,
                    "startOffset": 47894
                }
            },
            "secId": "s0070",
            "sentence": "The incidence of AEs with a fatal outcome reflected the age of participants [13,14], and was balanced between RZV and placebo recipients.",
            "startOffset": 47818,
            "title": "Discussion"
        },
        {
            "endOffset": 37789,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "All-grade solicited general symptoms tended to be more frequent after dose 2 compared to dose 1.",
            "startOffset": 37693,
            "title": "Reactogenicity"
        },
        {
            "endOffset": 47705,
            "parents": [],
            "secId": "s0070",
            "sentence": "The analysis performed considering grouped PTs referring to the same medical context of supraventricular tachyarrhythmias did not show any apparent differences between RZV and placebo recipients.",
            "startOffset": 47510,
            "title": "Discussion"
        },
        {
            "endOffset": 47818,
            "parents": [],
            "secId": "s0070",
            "sentence": "In addition, no biologically plausible mechanism by which RZV could cause supraventricular tachycardia is known.",
            "startOffset": 47706,
            "title": "Discussion"
        },
        {
            "endOffset": 51044,
            "parents": [],
            "secId": "s0070",
            "sentence": "In addition, some populations were excluded per protocol from the pivotal studies (e.g. patients with certain underlying diseases treated with high dose steroids or immune-modulators).",
            "startOffset": 50860,
            "title": "Discussion"
        },
        {
            "endOffset": 41296,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "By PT, the most frequently reported SAEs in both groups were pneumonia (RZV: 83 [0.57%], Placebo: 66 [0.45%]) and atrial fibrillation (RZV: 55 [0.38%], Placebo: 58 [0.40%], Table 2).",
            "startOffset": 41114,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 34279,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Fatal AEs, SAEs considered causally related to study vaccination by the investigators, and pIMDs (new onset and possible exacerbations) were collected during the entire study period.",
            "startOffset": 34097,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 39765,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Unsolicited AEs with medically attended visits were reported by 2751 (18.8%) RZV and 2774 (18.9%) placebo recipients during the 30D post-vaccination, and by 5834 (39.8) RZV and 5983 (40.8%) placebo recipients within 6 M post-last dose.",
            "startOffset": 39530,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 40278,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Within 30D post-last dose, 342 (2.3%) RZV and 327 (2.2%) placebo recipients reported at least one SAE.",
            "startOffset": 40176,
            "title": "Serious adverse events"
        },
        {
            "endOffset": 36012,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "RRs and their 95% CIs were calculated by Exact Tests conditional to the number of cases.",
            "startOffset": 35924,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31188,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 31187,
                    "startOffset": 31182
                },
                "b0025": {
                    "endOffset": 31187,
                    "startOffset": 31182
                }
            },
            "secId": "s0005",
            "sentence": "Two pivotal phase 3 efficacy trials (ZOE-50/70) demonstrated that RZV reduces the risk of HZ by over 90% in all age groups among adults \u226550YOA [4,5].",
            "startOffset": 31039,
            "title": "Introduction"
        },
        {
            "endOffset": 31322,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although the vaccine induces transient local and systemic reactions, no safety concerns were identified during these clinical trials.",
            "startOffset": 31189,
            "title": "Introduction"
        },
        {
            "endOffset": 35275,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants who received at least one dose of RZV/placebo.",
            "startOffset": 35132,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 36304,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The mean age of the participants was 68.6Y; 58.2% of those were female.",
            "startOffset": 36233,
            "title": "Study population"
        },
        {
            "endOffset": 48338,
            "parents": [],
            "secId": "s0070",
            "sentence": "Additionally, there were no clustering of similar events temporally associated with vaccination.",
            "startOffset": 48242,
            "title": "Discussion"
        },
        {
            "endOffset": 40061,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The incidence of unsolicited AEs with medically attended visits was similar between the RZV and Placebo groups in both males and females, in participants of any race, and in both age cohorts within the same period; incidences were also comparable between the age cohorts (Supplementary Table 3).",
            "startOffset": 39766,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 50576,
            "parents": [],
            "secId": "s0070",
            "sentence": "The statistical power of pre-licensure clinical trials to detect very rare events is limited due to the sample size.",
            "startOffset": 50460,
            "title": "Discussion"
        },
        {
            "endOffset": 52127,
            "parents": [],
            "secId": "s0075",
            "sentence": "TCH served as a paid consultant to GSK outside the submitted work.",
            "startOffset": 52061,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 33090,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Placebo consisted of 0.5 mL 150 mM NaCl solution.",
            "startOffset": 33041,
            "title": "Study vaccines"
        },
        {
            "endOffset": 39240,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The frequency of grade 3 unsolicited AEs was also higher in RZV than in placebo recipients within D0-D6 post-vaccination (Fig. 1) due to PTs covering the local and general symptoms reported by participants who were not part of the reactogenicity sub-cohort.",
            "startOffset": 38983,
            "title": "Unsolicited adverse events"
        },
        {
            "endOffset": 51640,
            "parents": [],
            "secId": "s0075",
            "sentence": "LO and TCH are inventors on a patent owned by GSK and relevant to RZV.",
            "startOffset": 51570,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 35498,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Analyses of unsolicited AEs, SAEs, and pIMDs were descriptive and, for each of these, percentages of participants with at least one event were calculated with their exact 95% Confidence Intervals (CIs) both per SOC and PT.",
            "startOffset": 35276,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 46496,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 46495,
                    "startOffset": 46485
                },
                "b0025": {
                    "endOffset": 46495,
                    "startOffset": 46485
                },
                "b0045": {
                    "endOffset": 46495,
                    "startOffset": 46485
                },
                "b0050": {
                    "endOffset": 46495,
                    "startOffset": 46485
                },
                "b0055": {
                    "endOffset": 46495,
                    "startOffset": 46485
                }
            },
            "secId": "s0070",
            "sentence": "Data published previously showed that RZV induces transient local and systemic reactions, such as injection site pain and, to a lesser extent, fatigue and myalgia [4,5,9\u201311].",
            "startOffset": 46322,
            "title": "Discussion"
        },
        {
            "endOffset": 48981,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 48980,
                    "startOffset": 48976
                }
            },
            "secId": "s0070",
            "sentence": "The theoretical risk of acquiring autoimmune diseases is considered to be driven by chronic inflammation, antigen mimicry and inflammation of target organs [23].",
            "startOffset": 48820,
            "title": "Discussion"
        },
        {
            "endOffset": 34345,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 34344,
                    "startOffset": 34341
                }
            },
            "secId": "s0025",
            "sentence": "SAEs were defined according to standard reporting guidelines [6].",
            "startOffset": 34280,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 34547,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Local AEs were considered related to study vaccination.",
            "startOffset": 34492,
            "title": "Collection of safety data"
        },
        {
            "endOffset": 45212,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The additional analysis of participants with pre-existing pIMDs revealed that 983 (6.7%) RZV and 960 (6.5%) placebo recipients had a pre-existing pIMD at enrollment (Table 5, Supplementary Fig. 3).",
            "startOffset": 45015,
            "title": "Potential immune-mediated diseases"
        },
        {
            "endOffset": 30285,
            "parents": [],
            "secId": "s0005",
            "sentence": "Herpes zoster (HZ) results from reactivation of latent varicella-zoster virus (VZV) in the dorsal root ganglia, usually years after primary VZV infection.",
            "startOffset": 30131,
            "title": "Introduction"
        },
        {
            "endOffset": 49664,
            "parents": [],
            "secId": "s0070",
            "sentence": "The analyses of the pooled study population presented here show no evidence for a statistical imbalance between RZV and placebo recipients.",
            "startOffset": 49525,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19303779",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "marta.x.lopez-fauqed@gsk.com",
                "first": "Marta",
                "initial": "M.",
                "last": "L\u00f3pez-Fauqued"
            },
            {
                "email": "laura.e.campora@gsk.com",
                "first": "Laura",
                "initial": "L.",
                "last": "Campora"
            },
            {
                "email": "frederique.x.delannois@gsk.com",
                "first": "Fr\u00e9d\u00e9rique",
                "initial": "F.",
                "last": "Delannois"
            },
            {
                "email": "mohamed.s.elidrissi@gsk.com",
                "first": "Mohamed",
                "initial": "M.",
                "last": "El Idrissi"
            },
            {
                "email": "cornelia.oostvogels@orange.fr",
                "first": "Lidia",
                "initial": "L.",
                "last": "Oostvogels"
            },
            {
                "email": "f.delooze@trialworks.com.au",
                "first": "Ferdinandus J.",
                "initial": "F.J.",
                "last": "De Looze"
            },
            {
                "email": "jdiezdomingo@gmail.com",
                "first": "Javier",
                "initial": "J.",
                "last": "Diez-Domingo"
            },
            {
                "email": "tch3768@gmail.com",
                "first": "Thomas C.",
                "initial": "T.C.",
                "last": "Heineman"
            },
            {
                "email": "himallal@yahoo.com",
                "first": "Himal",
                "initial": "H.",
                "last": "Lal"
            },
            {
                "email": "jmcelhaney@hsnri.ca",
                "first": "Janet E.",
                "initial": "J.E.",
                "last": "McElhaney"
            },
            {
                "email": "Shelly.McNeil@nshealth.ca",
                "first": "Shelly A.",
                "initial": "S.A.",
                "last": "McNeil"
            },
            {
                "email": "wilf@uow.edu.au",
                "first": "Wilfred",
                "initial": "W.",
                "last": "Yeo"
            },
            {
                "email": "fernanda.tavares@gsk.com",
                "first": "Fernanda",
                "initial": "F.",
                "last": "Tavares-Da-Silva"
            },
            {
                "email": null,
                "first": "Anitta",
                "initial": "A.",
                "last": "Ahonen"
            },
            {
                "email": null,
                "first": "Thiago Junquera",
                "initial": "T.J.",
                "last": "Avelino-Silva"
            },
            {
                "email": null,
                "first": "Jose Fernando",
                "initial": "J.F.",
                "last": "Barba-Gomez"
            },
            {
                "email": null,
                "first": "Johan",
                "initial": "J.",
                "last": "Berglund"
            },
            {
                "email": null,
                "first": "Carlos Brotons",
                "initial": "C.B.",
                "last": "Cuixart"
            },
            {
                "email": null,
                "first": "Covadonga",
                "initial": "C.",
                "last": "Caso"
            },
            {
                "email": null,
                "first": "Roman",
                "initial": "R.",
                "last": "Chlibek"
            },
            {
                "email": null,
                "first": "Won Suk",
                "initial": "W.S.",
                "last": "Choi"
            },
            {
                "email": null,
                "first": "Anthony L.",
                "initial": "A.L.",
                "last": "Cunningham"
            },
            {
                "email": null,
                "first": "Maria Guiseppina",
                "initial": "M.G.",
                "last": "Desole"
            },
            {
                "email": null,
                "first": "Peter",
                "initial": "P.",
                "last": "Eizenberg"
            },
            {
                "email": null,
                "first": "Meral",
                "initial": "M.",
                "last": "Esen"
            },
            {
                "email": null,
                "first": "Emmanuelle",
                "initial": "E.",
                "last": "Espi\u00e9"
            },
            {
                "email": null,
                "first": "Pierre",
                "initial": "P.",
                "last": "Gervais"
            },
            {
                "email": null,
                "first": "Wayne",
                "initial": "W.",
                "last": "Ghesquiere"
            },
            {
                "email": null,
                "first": "Olivier",
                "initial": "O.",
                "last": "Godeaux"
            },
            {
                "email": null,
                "first": "Iris",
                "initial": "I.",
                "last": "Gorfinkel"
            },
            {
                "email": null,
                "first": "David Shu Cheong",
                "initial": "D.S.C.",
                "last": "Hui"
            },
            {
                "email": null,
                "first": "Shinn Jang",
                "initial": "S.J.",
                "last": "Hwang"
            },
            {
                "email": null,
                "first": "Tiina",
                "initial": "T.",
                "last": "Korhonen"
            },
            {
                "email": null,
                "first": "Martina",
                "initial": "M.",
                "last": "Kovac"
            },
            {
                "email": null,
                "first": "Edouard",
                "initial": "E.",
                "last": "Ledent"
            },
            {
                "email": null,
                "first": "Edward",
                "initial": "E.",
                "last": "Leung"
            },
            {
                "email": null,
                "first": "Myron J.",
                "initial": "M.J.",
                "last": "Levin"
            },
            {
                "email": null,
                "first": "Silvia Narejos",
                "initial": "S.N.",
                "last": "Perez"
            },
            {
                "email": null,
                "first": "Jose Luiz",
                "initial": "J.L.",
                "last": "Neto"
            },
            {
                "email": null,
                "first": "Karlis",
                "initial": "K.",
                "last": "Pauksens"
            },
            {
                "email": null,
                "first": "Airi",
                "initial": "A.",
                "last": "Poder"
            },
            {
                "email": null,
                "first": "Maria Luisa Rodriguez",
                "initial": "M.L.R.",
                "last": "de la Pinta"
            },
            {
                "email": null,
                "first": "Lars",
                "initial": "L.",
                "last": "Rombo"
            },
            {
                "email": null,
                "first": "Tino F.",
                "initial": "T.F.",
                "last": "Schwarz"
            },
            {
                "email": null,
                "first": "Jan",
                "initial": "J.",
                "last": "Smetana"
            },
            {
                "email": null,
                "first": "Tommaso",
                "initial": "T.",
                "last": "Staniscia"
            },
            {
                "email": null,
                "first": "Juan Carlos",
                "initial": "J.C.",
                "last": "Tinoco"
            },
            {
                "email": null,
                "first": "Azhar",
                "initial": "A.",
                "last": "Toma"
            },
            {
                "email": null,
                "first": "Ilse",
                "initial": "I.",
                "last": "Vastiau"
            },
            {
                "email": null,
                "first": "Timo",
                "initial": "T.",
                "last": "Vesikari"
            },
            {
                "email": null,
                "first": "Antonio",
                "initial": "A.",
                "last": "Volpi"
            },
            {
                "email": null,
                "first": "Daisuke",
                "initial": "D.",
                "last": "Watanabe"
            },
            {
                "email": null,
                "first": "Lily Yin",
                "initial": "L.Y.",
                "last": "Weckx"
            },
            {
                "email": null,
                "first": "Toufik",
                "initial": "T.",
                "last": "Zahaf"
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            }
        ],
        "doi": "10.1016/j.vaccine.2019.03.043",
        "firstpage": "2482",
        "issn": "0264410X",
        "keywords": [
            "Reactogenicity",
            "Safety",
            "Vaccine",
            "Varicella-zoster virus"
        ],
        "lastpage": "2493",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials"
    }
}